Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Jamie A Kmak; Nikita Agarwal; Yuting He; Andreas M Heilmann; Vincent A Miller; Jeffrey S Ross; Sumanta Kumar Pal; Siraj M Ali; Deepak Kilari

doi:10.1159/000506625

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

Case Rep Oncol. 2020 Apr 27;13(1):456-461. doi: 10.1159/000506625. eCollection 2020 Jan-Apr.

Authors

Jamie A Kmak¹, Nikita Agarwal¹, Yuting He¹, Andreas M Heilmann¹, Vincent A Miller¹, Jeffrey S Ross^{1

2}, Sumanta Kumar Pal³, Siraj M Ali¹, Deepak Kilari³

Affiliations

¹ Foundation Medicine, Cambridge, Massachusetts, USA.
² Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
³ Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Abstract

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.

Keywords: Castration resistant; Everolimus; PTEN; Prostate cancer; mTOR.

Publication types

Case Reports